Los Angeles, CALIFORNIA35 Active Studies

Essential Tremor Clinical Trials in Los Angeles, CALIFORNIA

Find 35 actively recruiting essential tremor clinical trials in Los Angeles, CALIFORNIA. Connect with local research sites and explore new treatment options.

35
Active Trials
33
Sponsors
12,154
Enrolling

Recruiting Essential Tremor Studies in Los Angeles

RecruitingLos Angeles, CALIFORNIANCT06445946

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 ind...

1,572 participants
Ohio State University
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04474223

Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the 2nd trimester of pregnancy in an otherwise normally developing heart, is almost universally associated with mate...

1,300 participants
NYU Langone Health
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06628908

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN)....

1,100 participants
Vertex Pharmaceuticals Incorporated
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...

727 participants
Immunocore Ltd
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05099770

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-bio...

685 participants
Prokidney
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04064060

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the t...

665 participants
Celgene
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06486441

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemot...

640 participants
Gilead Sciences
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04108156

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibi...

634 participants
Hoffmann-La Roche
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06701903

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Stati...

570 participants
Intra-Cellular Therapies, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05640999

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enroll...

393 participants
Canadian Cancer Trials Group
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06233799

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing...

360 participants
National Institute on Drug Abuse (NIDA)
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05548296

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer....

353 participants
Acrivon Therapeutics
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06101745

Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery

The goal of this clinical trial is to determine if the drug Nizaracianine Triflutate can help surgeons see and avoid the ureters during abdominopelvic surgery. The ureters are thin-wall, collapsible t...

336 participants
Curadel Surgical Innovations, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06846320

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess ho...

315 participants
AbbVie
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05443126

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)...

265 participants
Ellipses Pharma
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06809595

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama...

250 participants
Mind Medicine, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05438212

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

This phase III trial compares the usual treatment of surgery after stereotactic radiosurgery (SRS) to receiving SRS before surgery in treating patients with cancer that has spread to the brain (brain ...

236 participants
NRG Oncology
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05611931

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) o...

220 participants
Karyopharm Therapeutics Inc
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06840496

To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatme...

210 participants
Biomed Industries, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05762107

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

The goal of this clinical trial is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabetes (T1D) who have been having low blood sugars ("hy...

186 participants
Zucara Therapeutics Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04462770

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children a...

150 participants
Epygenix
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06872125

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome....

150 participants
Stoke Therapeutics, Inc
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06388200

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mut...

150 participants
Ocugen
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04143724

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

This is a Phase 2a study to evaluate the safety and pharmacokinetics (PK) of luspatercept in pediatric participants with β-thalassemia. The study will be conducted in 2 parts for both transfusion-dep...

99 participants
Celgene
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05948592

Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

TP-102 is a novel bacteriophage cocktail comprised of 5 (five) lytic bacteriophages against Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii. TP-102 is being developed for to...

80 participants
Technophage, SA
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04634578

Bevacizumab Treatment For Type 1 ROP

Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Als...

80 participants
Jaeb Center for Health Research
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05295433

An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

The primary objective of this study is to evaluate the long-term safety of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT...

63 participants
ModernaTX, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT04899310

A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

This is a study of mRNA-3705 in participants with isolated elevated methylmalonic acid (MMA) due to methylmalonyl-coenzyme A (CoA) mutase (MUT) deficiency. The main goal of the study is to assess safe...

63 participants
ModernaTX, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06481592

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer....

60 participants
Iovance Biotherapeutics, Inc.
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06621251

Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection

TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making pathogens substantially more susceptible to established antibiotic treatmen...

60 participants
Trellis Bioscience LLC
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06739122

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months....

55 participants
Eli Lilly and Company
View Study Details
RecruitingLos Angeles, CALIFORNIANCT06401356

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionall...

50 participants
Novartis Pharmaceuticals
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05691465

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastati...

30 participants
National Cancer Institute (NCI)
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05504291

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

This phase II trial tests the safety and side effects of adding melphalan (by injecting it into the eye) to standard chemotherapy in early treatment of patients with retinoblastoma (RB). RB is a type ...

26 participants
Children's Oncology Group
View Study Details
RecruitingLos Angeles, CALIFORNIANCT05878860

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

This study will evaluate the safety and tolerability of ATSN-201 in male subjects ≥ 6 years of age with RS1-associated X-linked retinoschisis (XLRS)....

21 participants
Atsena Therapeutics Inc.
View Study Details

About Essential Tremor Clinical Trials in Los Angeles

Essential tremor is one of the most common movement disorders, causing involuntary shaking, most often in the hands. It is different from Parkinson's disease, though the two can be confused. Treatment includes medications, focused ultrasound, and deep brain stimulation for severe cases.

There are currently 35 essential tremor clinical trials recruiting participants in Los Angeles, CALIFORNIA. These studies are seeking a combined 12,154 participants. Research is being sponsored by Ohio State University, NYU Langone Health, Vertex Pharmaceuticals Incorporated and 30 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Essential Tremor Clinical Trials in Los Angeles — FAQ

Are there essential tremor clinical trials in Los Angeles?

Yes, there are 35 essential tremor clinical trials currently recruiting in Los Angeles, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Los Angeles?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Angeles research site will contact you about next steps.

Are clinical trials in Los Angeles free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Los Angeles studies also compensate for your time and travel.

What essential tremor treatments are being tested?

The 35 active trials in Los Angeles are testing new therapies including novel drugs, biologics, and treatment approaches for essential tremor.

Data updated March 2, 2026 from ClinicalTrials.gov